Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Stem-cell transplant for Hodgkin's lymphoma: does choice of therapy prior to high-dose treatment matter?

Nature Clinical Practice Oncology volume 2, pages 344–345 (2005)Cite this article

Access through your institution
Buy or subscribe

boxed-textJosting A et al. (2005) Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol 16: 116–123

Background

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Moskowitz CH et al. (2001) A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 97: 616–623

    Article  CAS  Google Scholar 

  2. Rodriguez J et al. (1999) ASHAP: A regimen for cytoreduction of refractory or recurrent Hodgkin's disease. Blood 93: 3632–3636

    CAS  PubMed  Google Scholar 

  3. Gianni AM et al. (1993) High-dose sequential chemoradiotherapy with peripheral blood progenitor cell support for relapsed or refractory Hodgkin's disease—a 6-year update. Ann Oncol 4: 889–891

    Article  CAS  Google Scholar 

  4. Gianni AM et al. (1997) High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 336: 1290–1297

    Article  CAS  Google Scholar 

  5. Ladetto M et al. (2002) High rates of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Blood 100: 1559–1565

    Article  CAS  Google Scholar 

  6. Tarella C et al. (2003) High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the Intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence. Cancer 97: 2748–2759

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Alexandra King, Assistant Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Professor of Medicine and Internist in the Department of Lymphoma and Myeloma at the University of Texas, M.D. Anderson Cancer Center in Houston, Texas, USA

    Fredrick B Hagemeister

Authors
  1. Fredrick B Hagemeister
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Fredrick B Hagemeister.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Glossary

NORTON–SIMON HYPOTHESIS

A mathematical model suggesting that more frequent dosing of chemotherapeutic agents minimizes tumor regrowth between doses; this theory forms the basis for dose-dense and sequential chemotherapy

COPP/ABVD

Cyclophosphamide, vincristine, procarbazine, and prednisone alternating with doxorubicin, bleomycin, vinblastine, and dacarbazine

BEACOPP

Bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone

DHAP

Dexamethasone, high-dose cytarabine, and cisplatin

PARTIAL RESPONSE (PR)

A greater than 50% reduction in measurable disease (the product of the largest tumor diameter and its perpendicular) lasting over 1 month

COMPLETE RESPONSE (CR)

Disappearance of all clinical and radiographic evidence of disease for at least 3 months

BEAM

Carmustine, etoposide, cytarabine and melphalan

MINI-BEAM

Low doses of carmustine, etoposide, cytarabine and melphalan

DEXA-BEAM

Dexamethasone combined with carmustine, etoposide, cytarabine and melphalan

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hagemeister, F. Stem-cell transplant for Hodgkin's lymphoma: does choice of therapy prior to high-dose treatment matter?. Nat Rev Clin Oncol 2, 344–345 (2005). https://doi.org/10.1038/ncponc0221

Download citation

  • Received:

  • Accepted:

  • Issue date:

  • DOI: https://doi.org/10.1038/ncponc0221

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing